Two Year Follow-Up On Biologics Use In 13 Centers-Data From The International Registry For Biologics In Systemic Lupus Erythematosus

Abstract

Only one biologic agent has been approved for use in SLE, but some are used off-label in various settings. To obtain systematic information regarding this, members of the SLICC group initiated the International Registry for Biologics in SLE (IRBIS). The entire registry contains data from 28 centers. Here, data are presented from 13 centers for which two-year follow-up was available on patients for whom a biologic was initiated in 2010-2011. The purpose with this study was to analyse the use of biologics in SLE, and assess the results achieved over the first two years after initiation.